Metoclopramidemonohydrochloride Accord

Metoclopramide Hydrochloride, the active ingredient in Metoclopramidemonohydrochloride Accord, is a dopamine D2 receptor antagonist presented as an oral dosage form for oral use. It is employed to alleviate nausea, vomiting, and to improve gastric motility in patients with gastroparesis or reflux disease.

GNH USA supplies Metoclopramidemonohydrochloride Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for global distribution. Customers benefit from competitive pricing and responsive technical support throughout the procurement process.

Metoclopramide Hydrochloride is used as a prokinetic and antiemetic acting on the gastrointestinal tract and the chemoreceptor trigger zone. - Nausea and vomiting: Reduces frequency and severity of episodes associated with chemotherapy, postoperative states, or gastrointestinal disorders. - Gastroparesis: Enhances gastric emptying, relieving symptoms such as early satiety, bloating, and nausea in patients with delayed stomach motility. - Gastro‑oesophageal reflux disease: Improves lower oesophageal sphincter tone and gastric clearance, helping to control reflux symptoms.

Metoclopramide Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: Feeling of sleepiness or reduced alertness. - Fatigue: Generalized lack of energy. - Restlessness: Uncomfortable urge to move, often described as akathisia. - Diarrhea: Loose, frequent stools. - Dry mouth: Reduced salivation leading to a dry oral cavity. - Headache: Mild to moderate head pain.

Serious or Rare Side Effects: - Extrapyramidal symptoms: Involuntary muscle movements, tremor, or rigidity. - Tardive dyskinesia: Potentially irreversible facial or limb movements with long‑term use. - Neuroleptic malignant syndrome: Life‑threatening reaction with fever, muscle rigidity, and autonomic instability. - Depression or suicidal thoughts: Mood changes requiring immediate medical attention. - Seizures: Rare occurrence of convulsive episodes. - Severe allergic reaction: Rash, swelling, or anaphylaxis.

Before prescribing Metoclopramide Hydrochloride, clinicians should consider several safety precautions to minimize risks. - Assess renal function: Adjust use in patients with severe renal impairment. - Monitor for extrapyramidal symptoms: Observe for signs of involuntary movements, especially during early therapy. - Use lowest effective dose: Limit duration to the shortest period necessary to achieve therapeutic goals. - Avoid in known hypersensitivity: Discontinue if allergic reactions occur. - Caution in pregnancy: Use only if potential benefit outweighs potential risk to the fetus. - Store at below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Metoclopramide Hydrochloride can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): Combined dopamine blockade may intensify extrapyramidal effects. - Monoamine oxidase inhibitors (MAOIs): May increase risk of hypertensive crisis or serotonin syndrome. - CNS depressants (e.g., benzodiazepines, opioids): Additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Opioid analgesics: May enhance gastrointestinal motility effects, requiring dose adjustment. - Selective serotonin reuptake inhibitors (SSRIs): Potential for increased serotonergic activity. - Antihistamines (e.g., diphenhydramine): May augment central nervous system side effects. - Anticholinergic agents: May counteract prokinetic action, reducing therapeutic benefit.